{
    "clinical_study": {
        "@rank": "30017", 
        "arm_group": {
            "arm_group_label": "Mifepristone-misoprostol", 
            "arm_group_type": "Experimental", 
            "description": "Women will receive 200mg oral mifepristone followed in 24-48h by 800mcg buccal misoprostol"
        }, 
        "brief_summary": {
            "textblock": "This open-label study is being conducted to determine whether a mifepristone-misoprostol\n      regimen for uterine evacuation which consists of 200 mg mifepristone followed 24 hours later\n      by 800 mcg buccal misoprostol is acceptable to women and providers and feasible for\n      introduction in public sector facilities in Bangladesh. It will also determine the\n      feasibility of women availing the option of taking their dose of misoprostol outside the\n      facility."
        }, 
        "brief_title": "Introducing Mifepristone-Misoprostol for Menstrual Regulation in Public Sector Facilities in Bangladesh", 
        "completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Menstrual Regulation", 
        "detailed_description": {
            "textblock": "This open-label study is being conducted to determine whether a mifepristone-misoprostol\n      regimen for uterine evacuation which consists of 200 mg mifepristone followed 24 hours later\n      by 800 mcg buccal misoprostol is acceptable to women and providers and feasible for\n      introduction in public sector facilities in Bangladesh. It will also determine the\n      feasibility of women availing the option of taking their dose of misoprostol outside the\n      facility.\n\n      The specific aims of this project are as follows:\n\n        -  Assess whether a uterine evacuation regimen that allows women the option of taking\n           their misoprostol outside the facility and which consists of 200 mg mifepristone\n           followed 24 hours later by 800 mcg buccal misoprostol is feasible for introduction in a\n           range of clinical settings in government facilities in Bangladesh;\n\n        -  Determine whether a mifepristone-misoprostol regimen for uterine evacuation is\n           acceptable to women and providers; and\n\n        -  Determine what proportion of women, if offered the choice, would prefer to take\n           misoprostol in the facility and what proportion would prefer to take it outside the\n           facility."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Be willing and able to sign consent forms;\n\n          -  Be eligible for menstrual regulation (MR) services according to clinician's\n             assessment;\n\n          -  Be willing to undergo a surgical evacuation if necessary;\n\n          -  Be willing to provide a urine sample prior to administration of the mifepristone\n\n          -  Have ready and easy access to a telephone and\n\n          -  Agree to comply with the study procedures and visit schedule\n\n        Exclusion Criteria:\n\n          -  \u2022 Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass;\n\n               -  Chronic renal failure;\n\n               -  Concurrent long-term corticosteroid therapy;\n\n               -  History of allergy to mifepristone, misoprostol or other prostaglandin;\n\n               -  Hemorrhagic disorders or concurrent anticoagulant therapy;\n\n               -  Inherited porphyrias; or\n\n               -  Other serious physical or mental health conditions."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1800", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01798017", 
            "org_study_id": "1004"
        }, 
        "intervention": {
            "arm_group_label": "Mifepristone-misoprostol", 
            "description": "Women will receive 200mg mifepristone followed in 24-48h by 800mcg bucccal misoprsotol", 
            "intervention_name": "Mifepristone and misoprostol", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Mifepristone", 
                "Misoprostol"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "menstrual regulation", 
            "mifepristone", 
            "misoprostol"
        ], 
        "lastchanged_date": "March 8, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aminbazar", 
                        "country": "Bangladesh", 
                        "state": "Dhaka Division"
                    }, 
                    "name": "Aminbazar Rural Dispensary"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tetuljhora", 
                        "country": "Bangladesh", 
                        "state": "Dhaka Division"
                    }, 
                    "name": "Tetulzhora UH&FWC"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Savar", 
                        "country": "Bangladesh", 
                        "state": "Dhaka"
                    }, 
                    "name": "MCH-Unit, Upazilla Health Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chandrapur", 
                        "country": "Bangladesh", 
                        "state": "Rajshahi"
                    }, 
                    "name": "Chartarapur UH & FWC"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Goyespur", 
                        "country": "Bangladesh", 
                        "state": "Rajshahi"
                    }, 
                    "name": "Goyeshpur UH &FWC"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pabna", 
                        "country": "Bangladesh", 
                        "state": "Rajshahi"
                    }, 
                    "name": "MCH Unit, Sadar Upazilla"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pabna", 
                        "country": "Bangladesh", 
                        "state": "Rajshahi"
                    }, 
                    "name": "Pabna MCWC"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dhaka", 
                        "country": "Bangladesh"
                    }, 
                    "name": "Mohammadpur Fertility Services and Training Center"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Bangladesh"
        }, 
        "number_of_arms": "1", 
        "official_title": "Introducing Mifepristone-Misoprostol for Menstrual Regulation in Public Sector Facilities in Bangladesh", 
        "overall_contact": {
            "email": "hbracken@gynuity.org", 
            "last_name": "Hillary Bracken, PhD", 
            "phone": "212.448.1230"
        }, 
        "overall_official": [
            {
                "affiliation": "Gynuity Health Projects", 
                "last_name": "Hillary J Bracken, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "International Centre for Diarrhoeal Disease Research, Bangladesh", 
                "last_name": "Laura Reichenbach, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Bangladesh: Bangladesh Medical Research Council", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "successful menstrual regulation without the need for a surgical evacuation", 
            "safety_issue": "Yes", 
            "time_frame": "14 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01798017"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Gynuity Health Projects", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gynuity Health Projects", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}